Journal · Updated 2026-08-11
GLP-1s and Heart Health: What SELECT Proved, and Who It Changed the Math For
By the GLP1ProviderFinder Research Desk · Medically reviewed by Dr. A. Goher, MD · Last reviewed 2026-08-11 · How we verify
The short answer
SELECT is the trial that moved this class from "weight drug with benefits" to cardiovascular medicine: across roughly seventeen and a half thousand adults with established cardiovascular disease and overweight or obesity — none with diabetes — semaglutide 2.4 mg reduced major adverse cardiac events (heart attack, stroke, cardiovascular death) by about twenty percent versus placebo over multi-year follow-up, a result that earned Wegovy an FDA cardiovascular-risk-reduction indication in 2024. Two consequences travel with the number: clinically, secondary prevention in the overweight-with-CVD population now includes this drug on evidence, not inference; financially, the CV indication is another coverage door — the same second-path logic as sleep apnea's — through weight-drug carve-outs.
Reading SELECT precisely
The precision matters because the claim gets stretched in both directions. What the trial enrolled: adults forty-five and up with prior heart attack, stroke, or peripheral arterial disease and a BMI of twenty-seven or higher — secondary prevention, established disease. What it showed: a relative MACE reduction around twenty percent (absolute benefit in the low single digits over the trial's years, as secondary-prevention numbers run), with the benefit appearing early enough and tracking weight loosely enough that mechanisms beyond the scale — anti-inflammatory, metabolic — are the live scientific discussion. What it didn't show: the same for primary prevention (no established disease), for other agents by extension (tirzepatide's dedicated CV-outcomes program is its own trial, ongoing), or for compounded products (evidence attaches to the approved drug). The class-adjacent real-world signals — like 2026 meta-analysis work associating GLP-1 therapy with fewer major limb events in peripheral arterial disease — point the same direction with observational caveats attached.
Who this changes the math for
The profile SELECT speaks to directly: overweight or obese, with a cardiac or vascular event history, without diabetes — the population insurers historically stranded between indications, now holding a trial with their name on it. The moves: raise the CV indication explicitly in the prescribing conversation; if coverage excludes weight management, file the prior authorization under cardiovascular risk reduction with the cardiac history documented; and fold the medication into — never instead of — the secondary-prevention stack (statins, blood-pressure control, antiplatelets as prescribed), whose components also get re-dosed as weight falls, per the pattern our re-dosing notes keep flagging. For everyone outside the studied profile, SELECT is context rather than a claim — encouraging class biology, not a personal promise — and the clinician holding your chart remains the translation layer.
Questions people ask
What did the SELECT trial show?
In ~17,600 adults with established cardiovascular disease and overweight/obesity (no diabetes), semaglutide 2.4 mg reduced major adverse cardiac events — heart attack, stroke, CV death — by about 20% versus placebo over multi-year follow-up, earning Wegovy an FDA cardiovascular indication in 2024.
Does SELECT apply to everyone taking GLP-1s?
No — it studied secondary prevention: prior heart attack, stroke, or peripheral arterial disease, BMI ≥27, no diabetes. Primary prevention, other agents (tirzepatide's CV-outcomes trial is separate and ongoing), and compounded products sit outside its claim.
Can heart disease get Wegovy covered when weight-loss drugs are excluded?
Often — the cardiovascular-risk-reduction indication is a second coverage door, like sleep apnea's for Zepbound. File the prior authorization under the CV indication with the cardiac history documented; carve-outs are indication-specific more than plans advertise.
This article is pricing research, not medical advice. Verify figures at the provider's checkout. Nothing here is medical advice.